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AdolescentsAbstract Background: Obesity and/or insulin resistance have gained increasing attention as the
core manifestations of metabolic syndrome.
Objective: To evaluate insulin resistance according to homeostasis model assessment of insulin
resistance index HOMA-IR in obese children and adolescents with or without metabolic syndrome
at risk of type 2 diabetes mellitus.
Design and subjects: 60 obese children and adolescents were recruited, metabolic syndrome was
diagnosed according to the modiﬁed WHO criteria adapted for children and adolescents. Insulin
resistance was calculated using the HOMA-IR.
Results: Metabolic syndrome (MS) was found in 42 subjects (70%), using modiﬁed WHO guide-
lines for diagnosing MS. On comparing MS-related parameters between the groups with (MS+)
and without metabolic syndrome (MS), median body mass index, waist circumference, waist/
height ratio, and blood pressure, total cholesterol and triglyceride were signiﬁcantly higher in the
MS + group. Basal insulin level as well as HOMA-IR was also signiﬁcantly different between
MS+ and MS-groups. The presence of insulin resistance according to HOMA-IR was identiﬁed
in 53% of obese children and adolescents. This HOMA-IR age and sex limit was exceeded by
70% children in the MS + group, but only by 43% children in the MS-group (p< 0.001).
HOMA-IR was positively correlated with the majority of anthropometric and biochemical param-
eters. The correlation was strongest with body mass index, waist circumference and diastolic blood
pressure.
Conclusions: HOMA-IR might be a reliable surrogate measure of insulin resistance and a strong
predictor of type 2 diabetes in obese adolescents allowing the development of preventive measures
and treatment when needed.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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The prevalence of overweight and obesity in children is
increasing worldwide at an alarming rate in both developing
and developed countries.1 Obesity is associated with a hetero-
geneity of metabolic abnormalities, e.g., dyslipidemia, insulin
resistance, hyperglycemia, and hypertension that may provide
a plausible biologic link between obesity and the increased risk
of cardiovascular morbidity and mortality. Metabolic syn-
drome (MS) has been deﬁned as a cluster of risk factors for
atherosclerosis that include insulin resistance, dyslipidemia,
abdominal obesity and often hypertension. The clustering of
these risk factors for cardiovascular disease (CVD) is referred
to as (MS).2,3 Patients with MS are at increased risk of cardio-
vascular disease (CVD) and type 2 diabetes mellitus (DM).
Obesity and/or insulin resistance (IR) have gained increasing
attention as the core manifestations of the syndrome.4 MS
has generated a great deal of interest in recent years, comprised
of a constellation of anthropometric, physiologic, and bio-
chemical abnormalities, MS is a risk factor for CVD and dia-
betes among adults.5 Diagnosis of MS aims to detect patients
at risk for cardiovascular and metabolic diseases.
The ﬁrst criterion of MS was presented in 1998 by the
World Health Organization (WHO), with emphasis on risk
factors for diabetes mellitus type 2 (T2D).6 In 2001, the Adult
Treatment Panel III (ATP) presented a deﬁnition of MS
focused on cardiovascular diseases. Finally, in 2007 the Inter-
national Diabetes Federation (IDF) developed a criterion
addressed to children aged 10 and older.7 Of MS components,
insulin resistance is believed to have a central role in metabolic
dysfunction, leading to problems such as hyperlipidemia,
hepatic steatosis, and atherosclerosis, which may progress to
cardiovascular diseases and T2D.8,9 The impairment of the
homeostatic relation between plasma insulin and glucose con-
centrations is a symptom of insufﬁcient insulin efﬁciency that
can be evaluated using the so called HOMA-IR.
Homeostatic model assessment for insulin resistance
(HOMA-IR), a relation between fasting glucose and insulin
has been recognized as the most sensitive and speciﬁc method
for measuring insulin resistance and risk for T2D.10
Aim of the work
The present study aimed to evaluate the prevalence of meta-
bolic syndrome and role of dysregulated glucose homeostasis
as consequences of obesity in children and adolescents at risk
for T2D.
Patients and methods
A total of 60 obese children and adolescents aged 8–18 years;
38 boys and 22 girls were enrolled from attendants of pediatric
genetic and endocrinology unit and pediatric outpatient clinic
of Menouﬁa University Hospitals, Egypt. Some female adoles-
cents especially from rural areas refuse to share in our study
that is why we have higher male: female ratio in our sample
of patients 1.7:1. We included in our study both children and
adolescents to have a relatively larger sample of patients. Writ-
ten consent had been taken from every child included in the
study or their participant parents. While collecting data, thosewho had secondary or known genetic causes of obesity were
excluded. Children and adolescents were assessed carefully in
terms of family history, blood pressure, and skin ﬁndings as
acanthosis nigricans.
Anthropometric assessments
All anthropometric measurements were taken with stress on
body height and weight that were measured in light clothes
using a portable stadiometer. Body mass index (BMI) was cal-
culated as weight divided by the square of the height (kg/m2).
Obesity was deﬁned according to both BMI and waist circum-
ference. BMI percentiles were calculated according to interna-
tional survey study.11 Subjects with BMIP 95 were deﬁned as
obese. To deﬁne abdominal obesity, waist circumference was
measured using non stretchable tape measure with the partici-
pant standing comfortably with his or her weight evenly dis-
tributed on both feet, and the feet about 12–15 cm apart.
The measurements were taken midway between the inferior
margin of the last rib and the crest of the ileum, in a horizontal
plane at the end of expiration.
Waist circumference (WC) was measured at the high point
of the iliac crest to the nearest 0.1 cm at the end of normal
expiration with a non stretchable tape. Hip circumference
was measured around the point with the maximum circumfer-
ence over the buttocks. Waist/hip ratio (WHR) and waist/
height ratio (WHtR) were calculated. Blood pressure was mea-
sured under standard conditions. Measurements were obtained
for each participant three times by the auscultation method
with appropriate cuff size after 20 min of rest.12 The average
of the last two blood pressure measurements was deﬁned as
hypertension if it was >95th percentile according to their
age and height percentile. All measures were evaluated accord-
ing to appropriate centiles.13
Pubertal staging was evaluated according to Tanner and
Whitehouse.14 Tanner stage I was deﬁned as pre-puberty,
Tanner stages II–IV as mid-puberty and Tanner stage V as
post puberty.15
Laboratory assays
All participants performed an oral glucose tolerance test
(OGTT) as follows: after a 12 h overnight fast, a venous cath-
eter was inserted in an ante-cubital vein; fasting blood sample
was withdrawn for estimation of fasting plasma insulin (FI),
and fasting blood glucose (FBG). Participants then ingested
1.75 mg/kg glucose (maximum 75 g), and blood samples were
withdrawn again after 30, 60, 90 and 120 min for estimation
of plasma insulin and blood glucose. The glucose oxidase
method was used in the determination of blood glucose levels.
Insulin levels were measured using a radioimmunoassay kit.
The venous blood sample was also analyzed for lipid proﬁle
including: total cholesterol (TC), triglycerides (TG), low den-
sity lipoprotein (LDL), and high density lipoprotein-choles-
terol (HDL). Serum lipids including, serum total cholesterol
(TC) and low density lipoprotein cholesterol (LDL-C), were
assayed by standard enzymatic methods with the use of
Beckman synchron CX5 chemistry analyzer (Diamond Diag-
nostics, USA).16 LDL is not directly measured in the routine
lipid panel; instead it is calculated by the Friedewald equation.
Prediction of metabolic syndrome 21This equation is: LDL Cholesterol = Total Choles-
terol  HDL cholesterol-(Triglycerides/5).17
For abnormal glucose homeostasis and hyperinsulinemia:
abnormal glucose homeostasis was deﬁned in the presence of
any of the following criterion: Impaired fasting glucose
(IFG) P100 mg/dl according to the new cutoff value recom-
mended by the American Diabetes Association (ADA).18 Glu-
cose at 120 min during the standard OGTT between 140 and
200 mg/dl was deﬁned as impaired glucose tolerance. Hyperin-
sulinism was deﬁned as fasting insulin and/or peak insulin
levels above cutoff values. For fasting insulin level, it was
deﬁned from any of the following norms for pubertal
stage: pre-pubertal (P15 mU/L), mid-puberty (Tanner stages
II–IV, P30 mU/L), and post-pubertal (P20 mU/L).19
The estimate of insulin resistance was calculated as pro-
posed by Matthewes et al. for homeostasis model assessment
for insulin resistance (HOMA-IR) index. HOMA-IR was com-
puted as follows: [fasting insulin (mU/L) · fasting glucose
(mmol/L)]/22.5.20 HOMA-IR cut-off value for diagnosing
insulin resistance/impaired insulin sensitivity from 95th per-
centile according to pubertal stage.21
Deﬁnition of components of MS was made following mod-
iﬁed WHO criteria adapted for children and adolescents.22
Diagnosis was made in the presence of obesity (BMI > 95th
percentile) plus two or more of the following risk factors:
Glucose homeostasis (hyperinsulinemia, pre-pubertal
(P15 mU/L), mid-puberty (P30 mU/L), and post-pubertal
(P20 mU/L), fasting glucose P100 mg/dl and impaired glu-
cose tolerance: 120 minP 140 mg/dl), elevated blood pressure
(systolic blood pressure (SBP) >95th percentile for age sex
and height), dyslipidemia (TG > 105 mg/dl for children
<10 years and >136 mg/dl for children P10 years, TC levels
are greater than cutoff point across sex and age groups. HDL-
Cholesterol <35 mg/dl).23 Children not fulﬁlling the MS diag-
nostic criteria were included to the group without metabolic
syndrome (MS).Table 1 Clinical characteristics of the studied groups.
Boys (N= 38)
Mean ± SD Med R
Age (Y) 12.05 ± 2.54 11 8–18
BMI (kg/m2) 28.35 ± 1.84 28.25 25.1–32.1
WC (cm) 92.36 ± 6.62 92 83–102
HC (cm) 85.81 ± 5.96 83.5 79–99
WHR 1.07 ± 0.06 0.005 0.98–1.28
WHtR 0.44 ± 0.10 0.45 0.30–0.70
SBP 119.87 ± 10.96 125 100–135
DBP 76.44 ± 6.25 75 65–85
TC (mg/dl) 184.47 ± 22.84 192 102–215
TG (mg/dl) 120.45 ± 22.75 128 80–165
HDL (mg/dl) 35.50 ± 2.92 35 31–42
LDL (mg/dl) 136.26 ± 5.89 136.5 120–145
FG (mg/dl) 90.15 ± 10.58 89.5 70–108
FI (mIU/dl) 20.19 ± 9.64 18.55 11.4–54.2
HOMA.IR 4.48 ± 2.0 4.18 2.09–10.55
Glucose 120 (mg/dl) 109.24 ± 6.71 108 98–124
SBP, systolic blood pressure; DPB, diastolic blood pressure; TC, total c
HDL, high density lipoproteins; LDL, low density lipoproteins; TG,
resistance; waist, waist circumference; hip, hip circumference.Statistical analysis
Quantitative data are expressed as mean ± standard deviation
and qualitative data are expressed as number and percent. All
parametric data were analyzed by the independent Student’s
t-test in categorical groups. All non-parametric data were
analyzed by Chi-square test. Pearson’s correlation coefﬁcient
was calculated to assess the strength of relationship between
HOMA-IR and other variables. A p-value of <0.05 was con-
sidered statistically signiﬁcant.
Results
The clinical characteristics of the study group of obese children
and adolescents are shown in Table 1. There were no major sex
differences except of greater WC and WHR in girls. Using
modiﬁed WHO criteria, MS was found in 42 subjects. Accord-
ing to the HOMA-IR index, IR was identiﬁed in 53% obese
children and adolescents, 70% of which were in the group of
MS+. The comparison of the clinical and laboratory features
between the groups with (MS+) or without metabolic syn-
drome (MS) is shown in Table 2. Median BMI, WC, WHtR,
and BP were higher in the MS + group. Serum levels of TG
were higher, and HDL-C levels were lower in the group with
MS than in those without. FG and glucose 120 were signiﬁ-
cantly higher in the MS + group. Basal insulin as well as
HOMA-IR was also signiﬁcantly different between MS+
and MS-groups. HOMA-IR was positively correlated with
major MS-related parameters. The correlation was strongest
with BMI, WC and DBP (Table 3).
Discussion
The prevalence of obesity among children and adolescents is
progressively increasing around the world.24 MS is highlyGirls (N= 22) t test P-value
Mean ± SD Med R
12.50 ± 2.17 12 9–18 0.69 0.493
27.84 ± 1.91 27.6 25.2–32.1 1.02 0.311
87.90 ± 4.84 88 80–101 2.99 0.004
88.31 ± 5.19 88.5 80–96 1.64 0.107
0.99 ± 0.04 0.97 0.94–1.09 4.96 <0.001
0.44 ± 0.10 0.40 0.30–0.60 4.96 0.944
120.36 ± 8.31 77.5 100–135 0.19 0.844
76.81 ± 4.76 70 70–85 0.24 0.811
190.05 ± 9.64 190 165–202 1.05 0.213
101.91 ± 19.78 93 82–140 3.18 0.002
35.22 ± 2.50 35 31–42 0.36 0.715
136.05 ± 3.81 135.5 130–142 0.17 0.863
95.90 ± 22.04 92 70–183 1.36 0.178
21.49 ± 10.62 19.05 11.6–38.5 0.48 0.630
4.98 ± 2.25 4.42 2.32–11.0 0.88 0.380
111.0 ± 6.45 108 102–124 0.99 0.324
holesterol; FG, fasting blood glucose level; FI, fasting insulin level;
triglycerides; HOMA-IR, homeostasis model assessment of insulin
Table 3 Correlation between HOMA-IR and the studied
parameters in our patients.
Parameters HOMA-IR
r P value
BMI (kg/m2) 0.78 <0.001
WC (cm) 0.63 <0.001





TC (mg/dl) 0.48 0.032
TG (mg/dl) 0.06 0.664
HDL (mg/dl) 0.22 0.250
LDL (mg/dl) 0.26 0.049
Table 2 Clinical characteristic differences between studied groups (MS+ vs. MS).
MS + No (%) 42(70) MS – No (%) 18(30) t test P-value
Mean ± SD Med R Mean ± SD Med R
Sex No (%)
M 26(62) 12(66.7) Chi 2 0.12 0.726
F 16(38) 6(33.3)
Age (Y) 12.52 ± 2.13 12.5 8–18 11.50 ± 2.89 11 8–18 1.52 0.132
BMI (kg/m2) 28.97 ± 1.53 28.80 26.4–32.1 26.29 ± 1.08 26.1 25.1–28.7 6.71 <0.001
WC (cm) 92.02 ± 5.87 92 83–102 87.72 ± 6.62 84 80–102 2.50 0.015
HC (cm) 88.04 ± 5.84 88.5 80–99 83.66 ± 4.37 81 79–91 2.84 0.006
WHR 1.04 ± 0.07 1.04 0.94–1.26 1.04 ± 0.08 1.03 0.95–1.28 0.11 0.912
WHtR 0.45 ± 0.09 0.48 0.30–0.60 0.44 ± 0.11 0.40 0.30–0.70 0.30 0.006
SBP 123.74 ± 7.53 125 110–135 111.44 ± 9.93 110 100–125 5.25 <0.001
DBP 78.45 ± 4.99 80 70–85 72.22 ± 4.91 70 65–80 4.44 <0.001
TC (mg/dl) 194.29 ± 10.75 193 165–215 168.89 ± 22.72 180 102–190 4.52 <0.001
TG (mg/dl) 119.05 ± 23.37 128 84–165 101.91 ± 18.28 94.5 80–132 3.20 0.003
HDL (mg/dl) 34.11 ± 1.67 35 31–38 38.38 ± 2.47 38 33–42 7.80 <0.001
LDL (mg/dl) 137.69 ± 4.49 138 130–145 132.67 ± 5.12 133 120–142 3.80 <0.001
FG (mg/dl) 90.15 ± 10.58 92 70–183 95.90 ± 22.04 81 73–108 2.17 0.033
FI (mIU/dl) 23.72 ± 10.38 21.35 11.8–54.2 13.53 ± 2.55 12.5 11.4–19.8 5.95 <0.001
HOMA-IR 5.43 ± 2.02 4.8 2.59–11.01 2.89 ± 0.67 2.48 2.09–4.5 7.04 <0.001
Glucose 120 (mg/dl) 111.48 ± 6.37 110 101–124 106.17 ± 5.74 104.5 98–121 3.04 0.004
MS+: with metabolic syndrome.
MS: without metabolic syndrome.
22 N.F. Barseem, M.A. Helwaprevalent within the adult population worldwide and is becom-
ing a serious problem in the pediatric population as well.
Unfortunately; there is no standard deﬁnition of MS for use
in pediatric populations. In this study, we used modiﬁed
WHO criteria with cutoff values for children and adolescents,
although small number of obese children and adolescents, it is
important to determine MS risk in obese children.25,26 The
prevalence of MS was 70% among our patients, mainly post
pubertal. This indicates the severity of the problem among
our population. It has been suggested that ethnic differences
play a role in the prevalence of obesity related cardio-meta-
bolic complications. Recent reports show that the Middle East
and North Africa have the highest obesity and diabetes preva-
lence among young adults.27
There has been debate about the extent to which the meta-
bolic syndrome deﬁnes the risk of CVD associated with insulinresistance beyond the risk associated with classic CVD risk fac-
tors (obesity, HDL, triglycerides, and blood pressure).28
Therefore, it would be useful to understand the extent to which
the presence of the syndrome is associated with IR. Several
studies from different populations were conducted to establish
the role of HOMA-IR and abnormal glucose homeostasis to
deﬁne MS in obese adolescents.29,30 This present study ana-
lyzed abnormal glucose homeostasis, HOMA-IR values and
lipid proﬁle in obese children and adolescents in both sexes,
also taking into account anthropometric measurements associ-
ated with MS.
In our study, MS showed no association with age. This may
be inﬂuenced by heterogeneity of pubertal status in different
chronological ages. In the same way there was no association
between gender and MS, conﬂicting data exist on this subject
since there are publications showing higher frequencies of
MS in males, others showing a slightly higher prevalence in
females or as in the present work, showing no signiﬁcant dif-
ference according to gender.31 In this study, when considering
anthropometric measurements, a signiﬁcant difference was
observed in obese children with MS+ regarding BMI, WC
and WHtR. Previous studies have shown that WC and WHtR
are good predictors of IR in adolescents. Khoury et al. (2013)
reported that WC can be used as a well accepted marker for
assessing the cardio metabolic risk and should be included as
part of routine screening of obese children and adolescents.32
Insulin resistance is commonly associated with obesity, and
HOMA-IR is a sensitive and speciﬁc method for its determina-
tion.33 However, there is no consensus on HOMA-IR cutoff
values for identifying MS in children and adolescents, thus
dramatically increasing the speciﬁcity and usefulness of
HOMA-IR for targeting research and intervention. This dis-
tinction will be useful in studies of population known to have
high genetic predisposition for diabetes in whom the range of
Prediction of metabolic syndrome 23HOMA-IR values is likely to be higher than other populations
with lower genetic susceptibility.34 Among the variable bio-
chemical parameters, there was a signiﬁcant difference in TG
level in those with MS (Table 2). The ﬁnding of TG as an asso-
ciated factor for MS is congruent with the report by Koury
et al. in a long follow-up study, where a signiﬁcant association
of high TG retained from childhood to adulthood with young
adult CVD was found. Also, the association of high TG from
childhood through adulthood with adult CVD could reﬂect the
presence of pediatric MS, a known predictor of adult CVD as
speculated by Koury et al. The importance of HOMA-IR
index as an adequate tool for determination of IR in obese
children was further supported by Makni et al. (2012) who
reported that HOMA-IR correlated better with the majority
of MS components in both sexes (Table 3). Sharma et al.
(2011) found that HOMA-IR is a stronger indicator of MS
in children than fasting blood glucose.35 Our results showed
higher rates of insulin resistance and lower rates of glucose
intolerance, and none of the patients in the study had FG level
P110 mg/dl so, diagnosing MS according to the adapted
WHO criteria, considering cutoff values for IFG is 100 mg/dl
and abnormal glucose homeostasis, deﬁned in the presence
of hyperinsulinemia and/or impaired glucose tolerance is
important.36–40 It takes a long time before abnormal glucose
homeostasis progresses to impaired glucose tolerance, for this
reason, use of modiﬁed WHO criteria for early diagnosis is
essential for preventive measures.41 So, our results based on
the adapted WHO criteria, are consistent with the literature
in that: insulin resistance parameters, indexed by HOMA-IR
as a corner stone for deﬁning IR, should be included among
the MS diagnostic criteria for children, to reduce the number
of cases with falsely negative diagnosis of metabolic
syndrome.42
Conclusion
In conclusion, the prevalence of MS among our patients is
high. HOMA-IR was identiﬁed in 53% of obese children
and adolescents, 70% of which were in the group of MS+.
HOMA-IR was positively correlated with major MS-related
parameters. The correlation was strongest with BMI and
WC. Basal insulin, FG and glucose 120 were signiﬁcantly
higher in the MS + group. So, dysregulated glucose
homeostasis mainly HOMA-IR plays an important role in
early identiﬁcation and prediction of MS in obese children
and adolescents which allows early intervention.Conﬂict of interest
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